The selective enrichment of both circulating B cells and CD4+ T cells in people with MS points to disease‐specific changes in lymphocyte fractions and thereby could reflect a distinct underlying mechanism per antibody‐associated CNS AID group, which requires validation and further investigation in the near future. This evidence concerns the gene CD4 and myeloid sarcoma.